Ketesse Dosage/Direction for Use

Adults: According to the nature and severity of pain, the recommended dosage is generally 12.5 mg every 4-6 hours or 25 mg every 8 hours. The total daily dose should not exceed 75 mg.
Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see Precautions).
Ketesse tablets are not intended for long term use and the treatment must be limited to the symptomatic period.
Elderly: In elderly patients it is recommended to start the therapy at the lower end of the dosage range (50 mg total daily dose). The dosage may be increased to that recommended for the general population only after good general tolerance has been ascertained.
Hepatic impairment: Patients with mild to moderate hepatic impairment should start therapy at reduced doses (50 mg total daily dose) and be closely monitored. Ketesse tablets should not be used in patients with severe hepatic impairment.
Renal impairment: The initial dosage should be reduced to 50 mg total daily dose in patients with mildly impaired renal function (creatinine clearance 60 - 89 ml/min) (see Precautions). Ketesse tablets should not be used in patients with moderate to severe renal impairment (creatinine clearance ≤ 59 ml/min) (see Contraindications).
Paediatric Population: Ketesse tablets has not been studied in children and adolescent. Therefore, the safety and efficacy in children and adolescents have not been established and the product should not be used in children and adolescent.
Method of administration: The tablet should be swallowed with a sufficient amount of fluid (e.g. one glass of water).
Concomitant administration with food delays the absorption rate of the drug (see Pharmacology: Pharmacokinetics under Actions), thus in case of acute pain it is recommended that administration is at least 30 minutes before meals.